Mr. Paul Thielking reports

CEDAR CLINICAL RESEARCH, BY NUMINUS, THE TOP ENROLLING CLINICAL RESEARCH SITE FOR MINDMED'S PHASE 2B STUDY EVALUATING MM-120

Numinus Wellness Inc.'s Cedar Clinical Research (CCR) is a top research site for MindMed's phase 2b study evaluating MM-120 (lysergide D-tartrate) for general anxiety disorder.

CCR's research clinic in Draper, Utah, is the top enrolling site for the research study -- having enrolled and dosed 19 clinical trial participants for the study to date. CCR also recently began enrolling volunteers for this trial at a second research clinic in Murray, Utah.

"We're excited to support MindMed in their clinical trial work, by evaluating new important treatments and protocols to address mental health disorders," said Paul Thielking, chief science officer, Numinus, and principal investigator at CCR Murray. "The fact that our Draper research clinic is the top enrolling site for the study underscores the quality of our clinical research capabilities and recruiting efforts."

The MindMed study aims to enroll up to 200 participants who will receive a single administration of 25 micrograms, 50 micrograms, 100 micrograms or 200 micrograms of MM-120, or placebo. Top-line results are expected to be announced by MindMed in late 2023.

About Numinus Wellness Inc.

Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model -- including psychedelic production, research and clinic care -- is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, the company is leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

About Mind Medicine (MindMed) Inc.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

We seek Safe Harbor.